SC75741 is a broad and efficient NF-κB inhibitor with an IC50 of 200 nM for p65. SC75741 blocks influenza viruses (IV) replication. SC75741 impairs DNA binding of the NF-κB subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspase activation and blocks caspase-mediated nuclear export of viral ribonucleoproteins.
性状
Solid
IC50 & Target[1][2]
p65
200 nM (IC50)
体外研究(In Vitro)
SC75741 (5 μM; 24-96 hours) inhibits long-term A549 cells proliferation.
SC75741 (1-10 μM; 5.5-65 hours) reduces A549 cells viability in a concentration-dependent manner indicating a cytostatic effect for A549 cells within a time frame of about 50 and 65?hours.
SC75741 (5 μM; 24 hours) strongly inhibits cleavage of the effector caspase 3 induced upon H7N7-infection.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay
Cell Line:
A549 cells
Concentration:
5?μM
Incubation Time:
24, 48, 72 and 96?hours
Result:
Inhibited long-term cell proliferation
Cell Viability Assay
Cell Line:
A549 cells
Concentration:
1, 2, 5 or 10?μM
Incubation Time:
5.5, 29, 50, 65 hours
Result:
Reduced cells viability in a concentration-dependent manner.
Western Blot Analysis
Cell Line:
MDCK cells
Concentration:
5?μM
Incubation Time:
24 hours
Result:
Inhibited cleavage of the effector caspase 3 induced upon H7N7-infection.
体内研究(In Vivo)
SC75741 (intraperitoneal injection; 15?mg/kg; for 2 days) leads to a reduced propagation of the H5N1 virus mRNA by 90% in the lungs of infected mice.
The plasma-levels of SC74751 (intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; for 3.5 and 6 hours) after i.v. administration decreases mono-exponentially and half-life is roughly 40 min. After i.p. administration, elimination of SC75741 seems to be limited by a slow uptake from the peritoneum and a half-life of 55 min is observed.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Inbred female C57BL/6 mice at the age of 6-8 weeks
Dosage:
15?mg/kg
Administration:
Intraperitoneal injection; for 2 days
Result:
Reduced the amount of viral mRNA by 90%.
Animal Model:
Inbred female C57BL/6 mice at the age of 6-8 weeks
Dosage:
5 mg/kg or 15 mg/kg
Administration:
Intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; 3.5 and 6 hours
Result:
Half-life was roughly 40 min and 55 min for i.v. and i.p. administration, respectively.